Clinical Trials at Avadel Pharmaceuticals
Sodium Oxybate is currently the only drug approved for the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients suffering from narcolepsy.
Avadel’s Micropump®-based formulation of sodium oxybate, FT218, is an investigational drug designed to be administered in one single dose, before bedtime, to treat EDS and cataplexy in patients suffering from narcolepsy.
On January 8, 2018, FDA granted orphan-drug designation to FT218 on the hypothesis that this investigational drug may be clinically superior to the currently marketed, twice-nightly sodium oxybate product. FT218 is currently being investigated in a Phase III clinical trial to determine if it is safe and effective for use in patients.
To find out more about our study, please visit our clinical trial website.
More information on narcolepsy can be found by visiting www.narcolepsynetwork.com.